News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bay Area's Sangamo BioSciences, Inc. (SGMO) Surges As Gene Editing Tech Make Cells Repel HIV


3/6/2014 8:22:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sangamo BioSciences' (SGMO) first clinical study, a phase 1 trial conducted on six HIV-positive patients over 12 weeks, demonstrates that the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection. This could potentially be a way to control HIV infection without the use of drugs. In the study, T-cells from the subjects were isolated and edited with ZFNs to make them resistant to the HIV virus by knocking out the CCR5 gene that encodes a coreceptor required for infection.

Help employers find you! Check out all the jobs and post your resume.

Read at Seeking Alpha
Read at RTT News
Read at Philadelphia Inquirer
Read at Fox News
Read at Washington Post

comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES